Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

2000 ◽  
Vol 27 (7) ◽  
pp. 766-777 ◽  
Author(s):  
Gregory A. Wiseman ◽  
Christine A. White ◽  
Michael Stabin ◽  
William L. Dunn ◽  
William Erwin ◽  
...  
Keyword(s):  
Phase I ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Ibritumomab Tiuxetan ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Yttrium 90

Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma

2007 ◽  
Vol 48 (9) ◽  
pp. 1736-1744 ◽  
Author(s):  
Jatin Shah ◽  
Wenquan Wang ◽  
V. Douglas Harrough ◽  
Wayne Saville ◽  
Ruby Meredith ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Ibritumomab Tiuxetan ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Yttrium 90

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma

2002 ◽  
Vol 29 (1) ◽  
pp. 87-92 ◽  
Author(s):  
Leo I Gordon ◽  
Thomas E Witzig ◽  
Greg A Wiseman ◽  
Ian W Flinn ◽  
Stewart S Spies ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Low Grade ◽  
Ibritumomab Tiuxetan ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Yttrium 90
Sign in / Sign up

Export Citation Format

Share Document